3 Exceptional High-Yielding Dividend Kings That Have Been Increasing Their Payouts for Over 60 Years
Stocks that pay dividends can make for great long-term investments. The best reason to invest in them is that they can generate recurring cash flow for you on an ongoing basis.
J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?
J&J shares gain 17.7% in three months, adding $63B to its market cap. Technical and pipeline momentum fuel investor interest.
3 Dividend Stocks to Hold Through Market Volatility This Fall
Stocks are rallying on the expectation that the Federal Reserve will cut interest rates by 25 basis points in September. That should be positive for corporate earnings.
If You'd Invested $1,000 in Johnson & Johnson (JNJ) Stock 5 Years Ago, Here's How Much You'd Have Today
How much would your $1,000 investment be worth if you'd bought Johnson & Johnson (JNJ -0.23%) five years ago? It would be worth $1,359.
J&J Painting Recognized with 2026 Consumer Choice Award for Painting Contractor in Waterloo
WATERLOO, ON / ACCESS Newswire / September 12, 2025 / J&J Painting, a trusted name in residential and commercial painting services, has been recognized with the 2026 Consumer Choice Award in the Pa...
After a couple years in purgatory, Johnson & Johnson is now having a strong year, says Jim Cramer
'Mad Money' host Jim Cramer revisits Johnson & Johnson's stock after a rough year for healthcare.
U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated
First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for reinduc...
Johnson & Johnson: JNJ Stock To $250?
Johnson & Johnson stock (NYSE: JNJ) has delivered a remarkable 24% return in 2025 even as the S&P 500 healthcare index declined 0.2%. This raises an important question: Is this outperformance groun...
Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Dir...
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has b...
Johnson & Johnson: A Safe Hold, But Lacking Catalysts To Beat The Market
This company boasts a strong history of dividend growth, making it attractive for income-focused investors. Currently, the stock appears slightly undervalued, but a clear catalyst is needed for it ...
Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival ...
Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year ...
Johnson & Johnson: A 6.9 Rating and What It Means for Investors
Explore the exciting world of Johnson & Johnson (JNJ -0.31%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into m...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell...
RYBREVANT® combination extends survival and significantly reduces common EGFR and MET resistance mutations seen with osimertinib-based treatment BARCELONA, Spain , Sept. 6, 2025 /PRNewswire/ -- Joh...
These 4 Dividend Stocks Are Money-Printing Machines
Some companies excel at generating cash. They operate mature businesses that produce significantly more profit than they need to support their continued expansion.
New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit ...
MADRID , Aug. 31, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously p...
Related Companies